Literature DB >> 15007158

Migraine throughout the life cycle: treatment through the ages.

Stephen Landy1.   

Abstract

Migraine seriously impairs the quality of life in those who suffer from it and exacts a high socioeconomic cost in lost productivity. About half of all persons with migraine go undiagnosed. To avoid misdiagnosis of migraine, clinicians must be prepared to recognize atypical presentations, including tension headache-like and "sinus" symptoms. Nonpharmacologic treatments, including relaxation training and thermal or EMG biofeedback training, may be appropriate for some patients. Pharmacotherapy for migraine may be acute or preventive. In prescribing treatment, the clinician should consider the characteristics of the patient's headaches, the patient's medication history and preferences, and co-morbidities. For acute treatment in patients with more severe migraine and those whose headaches respond poorly to nonsteroidal anti-inflammatory drugs or combination analgesics, migraine-specific agents, such as triptans, dihydroergotamine, and ergotamine, are recommended. Early intervention--identifying and treating the headache during the mild phase--is often a key to successful management. Preventive treatment of migraine may be appropriate to reduce the frequency, severity, and duration of migraine attacks, to improve the response to acute treatment, and to reduce disability. Clinicians who treat migraine must be aware of considerations specific to children, women, and the elderly.

Entities:  

Mesh:

Year:  2004        PMID: 15007158     DOI: 10.1212/wnl.62.5_suppl_2.s2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates.

Authors:  Frederick R Taylor; Robert G Kaniecki
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

Review 3.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Topiramate: the evidence for its therapeutic value in the prevention of migraine.

Authors:  Carole Nadin
Journal:  Core Evid       Date:  2005-06-30

Review 5.  Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.

Authors:  Carsten Oberhoff
Journal:  Support Care Cancer       Date:  2007-02-03       Impact factor: 3.359

6.  Modifications of antiepileptic drugs for improved tolerability and efficacy.

Authors:  Cecilie Johannessen Landmark; Svein I Johannessen
Journal:  Perspect Medicin Chem       Date:  2008-02-14

7.  Self-reported headache among the employees of a Swiss university hospital: prevalence, disability, current treatment, and economic impact.

Authors:  Emina Sokolovic; Franz Riederer; Thomas Szucs; Reto Agosti; Peter Stefan Sándor
Journal:  J Headache Pain       Date:  2013-03-26       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.